tivantinib

Drug Overview

Tivantinib is a highly specialized, investigational anti-cancer medicine. It belongs to an advanced category of treatments known as Targeted Therapy or “smart drugs.” Unlike traditional chemotherapy, which attacks all fast-growing cells in the body (both healthy and cancerous), targeted therapies are designed to focus on specific molecules and pathways that help tumors survive, grow, and spread.

• Generic Name: Tivantinib (often referred to in research literature by its experimental code, ARQ 197).
• US Brand Names: None yet. Because it is an investigational drug, it does not currently have a commercial brand name for public sale.
• Drug Class: Small molecule receptor tyrosine kinase inhibitor (TKI) / c-Met Inhibitor / Antimitotic Agent.
• Route of Administration: Oral (taken by mouth in the form of a capsule or tablet).
• FDA Approval Status: Currently investigational. Tivantinib is not yet approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for standard public use. It has been evaluated extensively in advanced clinical trials but is not available by a standard prescription.

What Is It and How Does It Work? (Mechanism of Action)

To understand how tivantinib works, it is helpful to look at the molecular behavior of cancer cells. Tivantinib is a Targeted Therapy that works through a dual mechanism to stop tumors from growing and spreading.

1. Blocking the c-Met Signaling Pathway:

Cells have protein structures on their outer surface called receptors, which act like satellite antennas receiving signals from the body. One important antenna is the “c-Met” receptor. When a specific bodily protein called Hepatocyte Growth Factor (HGF) binds to the c-Met receptor, it sends a powerful signal deep into the cell, commanding it to survive, multiply, and invade surrounding tissues. In many types of cancer, this c-Met pathway is hyperactive or mutated. Tivantinib was originally developed as a highly selective c-Met inhibitor. It is designed to lock onto the c-Met receptor and block these harmful signals. Without this continuous “grow and survive” signal, the cancer cell stops dividing.

2. Stopping Cell Division (Antimitotic Effect):

Recent molecular research has revealed that tivantinib also acts as a potent “antimitotic agent.” When any cell divides to make a copy of itself, it must build a temporary structural framework out of proteins called microtubules (made of tubulin). Tivantinib binds directly to this tubulin, preventing the cell from completing its internal framework. Because the cancer cell gets stuck in the middle of dividing, a state known as G2/M cell cycle arrest, it ultimately triggers its own death (apoptosis). This unique dual action makes it a fascinating “smart drug” in the realm of oncology.

FDA-Approved Clinical Indications

Because tivantinib is an investigational drug, it does not currently possess any official FDA-approved indications for routine clinical practice. However, it has been actively utilized and studied in approved clinical trials for the following purposes:

• Oncological Uses (In Clinical Trials):
  • Hepatocellular Carcinoma (HCC): Advanced liver cancer, specifically in patients whose disease has progressed after trying first-line systemic therapies like sorafenib.
  • Non-Small Cell Lung Cancer (NSCLC): Investigated as a treatment for advanced lung cancer, often in combination with other targeted drugs.
  • Colorectal Cancer: Studied for metastatic colon cancer.
  • Solid Tumors: Evaluated in various early-phase safety trials to see how it interacts with other standard chemotherapy drugs.
• Non-oncological Uses:
  • None. Tivantinib is strictly an anti-cancer agent.

Dosage and Administration Protocols

Because tivantinib is currently restricted to clinical research, the exact dosage is dictated by specific trial protocols. Early studies utilized higher doses, but researchers later adjusted the standard dosage downward to protect patients from severe drops in their white blood cell counts.

Clinical Efficacy and Research Results

Over the past decade, including comprehensive data reviews from 2020 to 2025, oncologists have heavily scrutinized the clinical efficacy of tivantinib, particularly for advanced liver cancer (HCC).

Initially, phase 2 clinical trials showed promising results. They suggested that a specific subgroup of patients, those with tumors showing high levels of the c-Met protein, lived significantly longer on tivantinib (median overall survival of 7.2 months) compared to a placebo (3.8 months).

However, subsequent large-scale phase 3 clinical trials (such as the METIV-HCC and JET-HCC trials) failed to meet their primary endpoints. In the METIV-HCC trial, the median overall survival for patients receiving tivantinib was 8.4 months, compared to 9.1 months for the placebo group. The drug did not demonstrate a statistically significant ability to prolong life or halt disease progression in these broader, late-stage studies. Furthermore, recent laboratory research from 2020 highlights that cancer cells can develop resistance to tivantinib, limiting its long-term effectiveness.

Safety Profile and Side Effects

Like all powerful cancer therapies, tivantinib can cause collateral damage to rapidly dividing healthy cells, particularly within the bone marrow and gastrointestinal tract.

Black Box Warning:

There is no FDA Black Box Warning for this medication because it is an investigational agent.

Common Side Effects (>10%)

• Neutropenia: A significant decrease in neutrophils (the white blood cells that fight infection).
• Fatigue: Mild to profound tiredness that does not improve with rest.
• Anemia: Low red blood cell counts, leading to pale skin, weakness, and shortness of breath.
• Thrombocytopenia: Low blood platelet counts, which can cause easy bruising and bleeding.
• Gastrointestinal Distress: Nausea, vomiting, diarrhea, and a general loss of appetite.

Serious Adverse Events

• Severe (Grade 3/4) Neutropenia: Dangerously low white blood cell levels that can lead to severe, life-threatening systemic infections.
• Febrile Neutropenia: Developing a high fever while white blood cell counts are depleted; this is considered a critical medical emergency.
• Interstitial Lung Disease (Rare): Severe inflammation and scarring of the lung tissue, leading to acute breathing difficulties.

Management Strategies

• Strict Blood Monitoring: Patients must undergo frequent Complete Blood Counts (CBC) to catch neutropenia before it becomes dangerous.
• Immediate Medical Intervention: If a patient experiences a fever during treatment, clinical protocols mandate an immediate pause of the drug and the rapid administration of broad-spectrum antibiotics.
• Dose Reduction: Many severe side effects are successfully managed by simply reducing the daily dosage of the medication.

Connection to Stem Cell and Regenerative Medicine

Cancer stem cells are a highly resilient sub-population of cells within a tumor that drive tumor growth and are notoriously resistant to standard treatments. Recent studies (2020-2025) have uncovered a critical relationship between tivantinib and a specific transport protein known as ABCG2, which is heavily overexpressed on the surface of cancer stem cells.

The ABCG2 protein acts as a molecular pump; its primary job is to push toxins, including chemotherapy and Targeted Therapies, out of the stem cell to ensure its survival. Research has demonstrated that tivantinib is a direct substrate of the ABCG2 pump. When tivantinib enters a cancer stem cell, the overactive ABCG2 pump immediately pushes the drug back out, rendering the treatment ineffective and causing multidrug resistance. Researchers in regenerative medicine and oncology are currently investigating ways to inhibit this ABCG2 pump, hoping that by disabling the pump, drugs like tivantinib can successfully remain inside and destroy these dangerous cancer stem cells.

Patient Management and Practical Recommendations

For patients enrolled in clinical trials evaluating tivantinib, strict adherence to safety protocols is mandatory to minimize toxicity and maximize potential benefits.

Pre-treatment Tests to be Performed

• Comprehensive Blood Panels: A baseline Complete Blood Count (CBC) and Comprehensive Metabolic Panel (CMP) to evaluate bone marrow health, liver enzymes, and kidney function.
• Pregnancy Test: A negative serum pregnancy test is strictly required for women of childbearing age, as the mechanism of the drug can cause severe fetal harm.
• Tumor Biopsy/Screening: In many trials, the tumor must be biopsied to check for “c-Met high” status before the patient is allowed to begin the medication.

Precautions During Treatment

Patients are considered immunocompromised while taking this medication. Extreme care must be taken to monitor for signs of infection. Any minor cut, scrape, or low-grade fever must be reported to the trial coordinators immediately.

“Do’s and Don’ts” List

• DO take the medication exactly as directed by your clinical trial team, typically twice daily with food.
• DO practice excellent hand hygiene and avoid crowded areas or people who are visibly ill.
• DO check your temperature daily and call your oncologist immediately if it reaches 100.4°F (38°C) or higher.
• DON’T alter your dosage or stop taking the medication without explicit permission from your trial physician.
• DON’T consume grapefruit, grapefruit juice, or St. John’s Wort, as these can severely alter how the body absorbs and processes oral cancer therapies.
• DON’T become pregnant or father a child during treatment. Highly effective contraception must be used throughout the trial and for several months after the final dose.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Tivantinib is an investigational therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) or other global health authorities for general clinical use. It is available exclusively through participation in formally approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, standard treatment options, and your potential eligibility for clinical trials. Do not start, stop, or change any medical treatment based on this document.